|
|
Vaccine Detail
|
Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: Autologous TARP Peptide-Pulsed Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007316
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- Antigen: TARP peptide
- TBXT
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- TARP
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Preparation: DCs are matured in vitro and pulsed with antigen before injection (Elster et al., 2016).
- Description: A cell-based cancer vaccine comprised of autologous dendritic cells pulsed with autologous T cell receptor gamma-chain alternate reading frame protein (TARP) peptide with potential immunostimulatory and antineoplastic activities. Upon intradermal administration, autologous TARP peptide-pulsed dendritic cell vaccine may stimulate anti-tumoral cytotoxic T lymphocyte (CTL) and antibody responses against TARP-expressing cancer cells, resulting in tumor cell lysis. The highly immunogenic nuclear protein TARP is commonly expressed in breast and prostate cancer cells. (NCIT_C85470).
This vaccine has been used in clinical trials involving prostate cancer. NCT02362451
|
| Host Response |
|
|
| References |
Elster et al., 2016: Elster JD, Krishnadas DK, Lucas KG. Dendritic cell vaccines: A review of recent developments and their potential pediatric application. Human vaccines & immunotherapeutics. 2016; 12(9); 2232-2239. [PubMed: 27245943].
NCIT_C85470: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C85470]
|
|
